| COVID-19 |
1 |
1 |
| Thromboembolism |
0 |
0.95 |
| Anticoagulation Therapy |
0 |
0.7 |
| Coronary Artery Disease (CAD) |
0 |
0.43 |
| Thrombosis |
0 |
0.35 |
| Cerebrovascular Accident |
0 |
0.32 |
| Artery |
0 |
0.26 |
| Antithrombotics |
0 |
0.24 |
| Cardiovascular Risk Management |
0 |
0.21 |
| Peripheral Artery Disease |
0 |
0.2 |
| Clinical Research |
0 |
0.17 |
| Heart |
0 |
0.17 |
| Hospital |
0 |
0.17 |
| Immunization |
0 |
0.17 |
| Ischemic Stroke |
0 |
0.17 |
| Pandemic |
0 |
0.17 |
| Venous Thromboembolism (VTE) |
0 |
0.15 |
| Heart Failure (HF) |
0 |
0.14 |
| Healthcare and Medical Technology |
0 |
0.1 |
| Body Mass Index |
0 |
0.09 |
| Cancer |
0 |
0.09 |
| Cardiovascular disease |
0 |
0.09 |
| Central Nervous System |
0 |
0.09 |
| Disability |
0 |
0.09 |
| Embolization |
0 |
0.09 |
| Infarction |
0 |
0.09 |
| Ischemia |
0 |
0.09 |
| Limb |
0 |
0.09 |
| Lung |
0 |
0.09 |
| Prophylaxis |
0 |
0.09 |
| Myocardial Infarction (MI) |
0 |
0.05 |
| Obesity |
0 |
0.05 |
| Vaccines |
0 |
0.05 |